-- For 2009, the company anticipates revenues of approximately $72.4 million (unaudited), a 34% increase over 2008.-- Cash, cash equivalents, short and long-term investments are anticipated to be approximately $31.8 million (unaudited) at December 31, 2009, compared with $29.7 million at December 31, 2008.-- The company expects 2010 sales revenue of $82 to $85 million, a 15% increase over 2009
SciClone and Sigma-Tau Announce Positive Preliminary Results in Clinical Study Examining ZADAXIN'S Ability to Enhance Response to H1N1 Vaccine Study Shows Increase in Seroconversion From 56% to 88% 21 Days After Vaccination
NEW YORK (AP) -- SciClone Pharmaceuticals Inc. reported a fourth-quarter profit on higher sales of the vaccine booster Zadaxin and lower costs.
The company earned $2.4 million, or 5 cents per share, compared with a loss of $3.1 million, or 7 cents per share, a year earlier. Revenue rose to $18.1 million from $15.3 million.
The results topped the average analyst estimate for a profit of 2 cents per share and revenue of $18 million, according to a survey by Thomson Reuters.
For the full year, SciClone Pharmaceuticals earned $11.9 million, or 25 cents per share, compared with a loss of $8.3 million, or 18 cents per share, in 2008. Revenue rose to $72.4 million from $54.1 million.
Looking ahead, the company expects profit between 31 cents per share and 35 cents per share on revenue between $82 million and $85 million in 2010.